Real-world patterns and outcomes in metastatic castration-resistant prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will analyze real-world treatment patterns, outcomes, and patient characteristics of adults with metastatic castration-resistant prostate cancer in the United States. Data will be drawn from the PRECISION data platform to understand how care is delivered outside of controlled trials. The analysis will describe demographics, therapies used, and clinical outcomes over time. No interventional procedures are planned; the study aims to characterize current practice and outcomes. Lead sponsor is Novartis Pharmaceuticals, with research activities centered in East Hanover, New Jersey.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Diagnosis of mCRPC between 01 January 2021 and 31 December 2025.
* Male sex at index, where index is the date of initial mCRPC diagnosis.
* Age 18 years at index.

Exclusion criteria:

• None

Where it's running

• Novartis
  East Hanover, New Jersey, United States Recruiting

Study contacts

• Study coordinator: Novartis Pharmaceuticals
• Email: novartis.email@novartis.com
• Phone: +41613241111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• FX-111 safety and pharmacokinetics in metastatic castration-resistant prostate cancer

  This study tests whether FX-111 is safe and can help treat metastatic castration-resistant prostate cancer in adult men.

  Recruiting at 7 sites Phase 1 Flare Therapeutics Inc. · Los Angeles, California and 9 other locations · NCT07719361

• Fractionated Stereotactic Radiotherapy Plus Second-Generation Antiandrogen in oligometastatic castration-resistant prostate cancer

  This study tests whether adding SBRT to a second-generation antiandrogen helps men with oligometastatic, castration-resistant prostate cancer see better outcomes.

  Recruiting at 6 sites Phase 2 Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Zaragoza, Aragon and 14 other locations · NCT07717268

• Pluvicto real-world use in metastatic castration-resistant prostate cancer

  This real-world study tests how well Pluvicto works in men with metastatic castration-resistant prostate cancer in the US and Germany.

  Recruiting Novartis · East Hanover, New Jersey · NCT07697989

• Real-world patterns and outcomes for mCRPC patients who have had ARPI, taxane, and 177Lu-PSMA-617

  This real-world study tests how patients with metastatic castration-resistant prostate cancer, who have already received an ARPI, a taxane, and 177Lu-PSMA-617, fare in US practice using PRECISION data.

  Recruiting Novartis · East Hanover, New Jersey · NCT07677267

• Pasritamig plus docetaxel versus docetaxel for metastatic castration‑resistant prostate cancer

  This trial tests whether adding pasritamig to standard docetaxel chemotherapy helps men with metastatic castration-resistant prostate cancer stay progression-free on scans longer than docetaxel alone.

  Recruiting at 165 sites Phase 3 Janssen Research & Development, LLC · Chandler, Arizona and 164 other locations · NCT07225946

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.